News & Blogs

Charles L. Hooper and David R. Henderson: Expensive Prescription Drugs Are a Bargain

The Inflation Reduction Act has eight provisions intended to reduce future drug prices. Some observers were surely pleased that Congress gave the Centers for Medicare and Medicaid Services new powers to negotiate with pharmaceutical companies. They shouldn’t have been. The Inflation Reduction Act won’t noticeably reduce inflation and it will do little or nothing to lower the cost of healthcare. Forcing drug companies to charge lower prices will likely lead to fewer new drugs. Virtually…

Learn More

AARP Has a Staggering Conflict of Interest

Kimberley Strassel poses an all-too-crucial question: “Whom Does AARP Serve?” (Potomac Watch, Aug. 5). It’s an inquiry we’ve had for quite some time, and unfortunately for AARP’s members, the answer isn’t seniors. Ms. Strassel notes that 2020 was the first time AARP was paid over $1 billion in corporate royalties, much of it derived from UnitedHealth Group. Compare that with the roughly $300 million AARP receives from membership dues, and the conflict becomes clear. Even with a conservative…

Learn More

Marion Mass: Wrong Diagnosis + Wrong Prescription = Congressional Malpractice

Supporters of the Inflation Reduction Act have made claims about lowering the cost of healthcare and prescription drugs. But the bill does neither and sets a dangerous precedent that will lead to less access to care and fewer cures for patients. In fact, not only does it harm healthcare – it funnels money toward the two entities that are currently the biggest problems in healthcare – Pharmacy Benefit Managers and insurers. The proposal claims to give the…

Learn More

Whom Does AARP Serve?

It’s been a decade since that infamous liberal ad showing then vice-presidential nominee Paul Ryan pushing granny off a cliff. Don’t expect a similar accusation today against the conflict-of-interest known as the AARP, no matter that the seniors’ group deserves it. The AARP, which claims to advocate policies that serve the interests of tens of millions of retirees, has gone all in for the giant tax-and-spend deal announced last week by Sen. Joe Manchin and Majority Leader Chuck Schumer. The…

Learn More

The Editorial Board: The Drug Pricing ‘Slippery Slope’

Progressives are disappointed with the tentative drug-pricing deal that Senate Majority Leader Chuck Schumer appears to have struck with West Virginia’s Joe Manchin. But no worries, says Vermont Rep. Peter Welch, the price controls are merely the start of what will be a long raid on drug makers to fund Democratic spending ambitions. The Senate drug agreement would require the Health and Human Services Secretary to “negotiate” prices for 10 of the top-spending drugs in…

Learn More

Steve Forbes: Democrats’ drug-pricing plan warrants disinformation flag for seniors

Senate Democrats are moving forward with a falsely advertised drug pricing plan. Liberals, and even maverick Sen. Joe Manchin (D-W.Va.), claim their newest plan will help lower drug costs for seniors and even drive down inflation. As always, however, the fine print says something else. In fact, the scheme would be a disaster for the development of life-extending, life-improving medicines and medical devices. Start with the money. The details show their proposal is more about…

Learn More

American Commitment to Seniors Launches Seven-Figure Ad Buy Slamming Washington Liberals’ Plan To Slash Medicare Prescription Drug Spending

Ad Highlights How Democrats’ Drug Pricing Proposal Would Harm Seniors and Raid Nearly $300 Billion From Medicare. CONTACT: Jon Decker ([email protected]) WASHINGTON, D.C. (July 28, 2022) — American Commitment’s Commitment to Seniors project has launched a new seven-figure initial ad buy, raising concerns about Washington liberals’ claim that their partisan spending bill “lowers seniors’ drug costs,” when actually, it siphons nearly $300 billion out of Medicare to unrelated spending. The ad is airing through August 5…

Learn More

Media Advisory: Senate Democrats and AARP Have Opportunity to Answer Critical Questions on Partisan Drug Pricing Proposal

***Media Advisory – Today: Capitol Hill Conference on Drug Pricing Proposal*** Senate Democrats and AARP Have Opportunity to Answer Critical Questions on Partisan Drug Pricing Proposal WASHINGTON – [7/27/22] — Today, Wednesday, July 27 at 3:00 p.m. EST, AARP CEO Jo Ann Jenkins and other advocates will join Senate Democrats at a press conference to discuss the partisan drug pricing proposal that will be voted on in the U.S. Senate in the coming days. Considering…

Learn More